Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) witj the KRAS-G12C mutation in adults who have received at least one prior systemic therapy. It is additionally approved in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluorouracil-, oxaliplatin– and irinotecan-based chemotherapy. 

The usual pathway consists of GTP binding to KRAS, aloowing downstream signalling through MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib, being a KRASG12C inhibitor, binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non-small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors. This enables blocking and KRAS signaling, inhibited cell growth, and promoted apoptosis specifically in KRAS G12C tumor cell lines. This product has inhibited KRASG12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib treatment led to tumor regressions and prolonged survival, and was associated with anti-tumor immunity in KRAS G12C models. 

There are no available data on Sotorasib use in pregnant women. Because of the potential for serious adverse reactions in breastfed children, women are advised not to breastfeed during treatment with Lumakras and for 1 week after the final dose. The safety and effectiveness of this product have not been established in pediatric patients. No overall differences in safety or effectiveness were observed between older patients and younger patients. No dosage modification is recommended in patients with mild to moderate hepatic impairment (Child Pugh A or B). The effect of severe hepatic impairment (Child-Pugh C) on the safety of LUMAKRAS is unknown. Monitor for sotorasib adverse reactions in patients with hepatic impairment more frequently since these patients may be at increased risk for adverse reactions including hepatotoxici

Pricing and availability: 

Sotorasib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for sotorasib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of sotorasib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy sotorasib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access: 

As sotorasib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like sotorasib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Sotorasib or Lumakras is available as 320 mg tablets in carton containing one bottle of 90 tablets with child-resistant closure and as 120 mg tablets in carton containing two bottles of 120 tablets or one bottle of 240 tablets with child-resistant closure, 

Import process:

1. Request submission for your medicine
   Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
2. Submission of an application (Form 12A)
   Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
3. Verification of documents
   We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
4. Permission to import
   Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
5. Sourcing the medicine
   Our sourcing team connects with authorized global suppliers to find the best sotorasib price in India, thus making it convenient to easily access Lumakras in India, and ensure authenticity before finalizing the offer.
6. Delivery of the medicine
   After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
3. Government-issued ID proof and proof of residence of the patient.
4. Import permit if applicable.  

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lumakras from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import sotorasib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

If you are exploring reliable options to buy Sotorasib (Lumakras) in India, expert assistance is available. For accurate pricing, availability updates, and end-to-end support with the import process, you may reach out to 24/7QualityMeds. Their team helps ensure compliant sourcing and smooth delivery so patients can access this essential therapy with confidence.